Coronaviruses (CoVs) comprise a polymorphic group of respiratory viruses causing acute inflammatory diseases in domestic and agricultural animals (chicken, pig, buffalo, cat, dog) Until recently, this infection in humans was mainly observed during the autumn-winter period and characterized by a mild, often asymptomatic, course The situation changed dramatically in 2003, when SARS outbreak caused by pathogenic CoV (SARS-CoV) was recorded in China A decade later, a new CoV outbreak occurred in the form of the Middle East respiratory syndrome (MERS-CoV), whereas in December 2019, SARS-CoV-2 (COVID-19) cases were recorded, which transformed within the first months of 2020 into the pandemic In all three cases, CoV disease led to severe bronchopulmonary lesions, varying from dry, debilitating cough to acute respiratory distress syndrome (ARDS) At the same time, multiple changes in innate immunity were noted most often manifested as a pronounced inflammatory reaction in the lower respiratory tract, featured by damaged type II pneumocytes, apoptosis, hyalinization of alveolar membranes, focal or generalized pulmonary edema Destructive processes in the respiratory tract were accompanied by migration of monocytes/macrophages and granulocyte neutrophils to the inflammatory focus Such events were accompanied by production of pro-inflammatory cytokines, which magnitude could ascend up to a cytokine storm SARS-CoV is characterized by symptoms of secondary immunosuppression, manifested by the late onset of interferon production and activation of NLRP3 inflammasomes â€“ the key inflammatory factor The reason for such reaction may be accounted for by CoV arsenal containing extensive set of structural and inflammatory proteins exerting pro-inflammatory and immunosuppressive properties Delayed IFN production allowed CoV to replicate actively and freely, and when type I IFN synthesis was eventually triggered, its activity was detrimental and accompanied by an aggravated infection course Thus, SARS can surely be referred to immune-dependent infections with a marked immunopathological component The purpose of this review was to describe some mechanisms underlying formation of innate immune response to infection caused by pathogenic coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) ;ÐšÐ¾Ñ€Ð¾Ð½Ð°Ð²Ð¸Ñ€ÑƒÑÑ‹ (CoV) Ð¿Ñ€ÐµÐ´ÑÑ‚Ð°Ð²Ð»ÑÑŽÑ‚ ÑÐ¾Ð±Ð¾Ð¹ Ð¿Ð¾Ð»Ð¸Ð¼Ð¾Ñ€Ñ„Ð½ÑƒÑŽ Ð³Ñ€ÑƒÐ¿Ð¿Ñƒ Ñ€ÐµÑÐ¿Ð¸Ñ€Ð°Ñ‚Ð¾Ñ€Ð½Ñ‹Ñ… Ð²Ð¸Ñ€ÑƒÑÐ¾Ð², Ð²Ñ‹Ð·Ñ‹Ð²Ð°ÑŽÑ‰Ð¸Ñ… Ð¾ÑÑ‚Ñ€Ñ‹Ðµ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ðµ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ Ñƒ Ð´Ð¾Ð¼Ð°ÑˆÐ½Ð¸Ñ… Ð¸ ÑÐµÐ»ÑŒÑÐºÐ¾Ñ…Ð¾Ð·ÑÐ¹ÑÑ‚Ð²ÐµÐ½Ð½Ñ‹Ñ… Ð¶Ð¸Ð²Ð¾Ñ‚Ð½Ñ‹Ñ… (ÐºÑƒÑ€Ñ‹, ÑÐ²Ð¸Ð½ÑŒÐ¸, Ð±ÑƒÐ¹Ð²Ð¾Ð»Ñ‹, ÐºÐ¾ÑˆÐºÐ¸, ÑÐ¾Ð±Ð°ÐºÐ¸) Ð£ Ð»ÑŽÐ´ÐµÐ¹ Ð¸Ð½Ñ„ÐµÐºÑ†Ð¸Ñ Ð´Ð¾ Ð½ÐµÐ´Ð°Ð²Ð½ÐµÐ³Ð¾ Ð²Ñ€ÐµÐ¼ÐµÐ½Ð¸ Ð½Ð°Ð±Ð»ÑŽÐ´Ð°Ð»Ð¾ÑÑŒ Ð¿Ñ€ÐµÐ¸Ð¼ÑƒÑ‰ÐµÑÑ‚Ð²ÐµÐ½Ð½Ð¾ Ð² Ð¾ÑÐµÐ½Ð½Ðµ-Ð·Ð¸Ð¼Ð½Ð¸Ð¹ Ð¿ÐµÑ€Ð¸Ð¾Ð´ Ð¸ Ñ…Ð°Ñ€Ð°ÐºÑ‚ÐµÑ€Ð¸Ð·Ð¾Ð²Ð°Ð»Ð°ÑÑŒ Ð»ÐµÐ³ÐºÐ¸Ð¼, Ð·Ð°Ñ‡Ð°ÑÑ‚ÑƒÑŽ Ð±ÐµÑÑÐ¸Ð¼Ð¿Ñ‚Ð¾Ð¼Ð½Ñ‹Ð¼, Ñ‚ÐµÑ‡ÐµÐ½Ð¸ÐµÐ¼ Ð¡Ð¸Ñ‚ÑƒÐ°Ñ†Ð¸Ñ Ñ€ÐµÐ·ÐºÐ¾ Ð¸Ð·Ð¼ÐµÐ½Ð¸Ð»Ð°ÑÑŒ, Ð² 2003 Ð³Ð¾Ð´Ñƒ, ÐºÐ¾Ð³Ð´Ð° Ð² ÐšÐ¸Ñ‚Ð°Ðµ Ð±Ñ‹Ð»Ð° Ð·Ð°Ñ€ÐµÐ³Ð¸ÑÑ‚Ñ€Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð° Ð²ÑÐ¿Ñ‹ÑˆÐºÐ° Ð°Ñ‚Ð¸Ð¿Ð¸Ñ‡Ð½Ð¾Ð¹ Ð¿Ð½ÐµÐ²Ð¼Ð¾Ð½Ð¸Ð¸, Ð²Ñ‹Ð·Ð²Ð°Ð½Ð½Ð¾Ð¹ Ð¿Ð°Ñ‚Ð¾Ð³ÐµÐ½Ð½Ñ‹Ð¼ CoV (SARS-CoV) Ð¡Ð¿ÑƒÑÑ‚Ñ 10 Ð»ÐµÑ‚ Ð²Ð¾Ð·Ð½Ð¸ÐºÐ»Ð° Ð½Ð¾Ð²Ð°Ñ Ð²ÑÐ¿Ñ‹ÑˆÐºÐ° CoV Ð² Ð²Ð¸Ð´Ðµ Ð±Ð»Ð¸Ð¶Ð½ÐµÐ²Ð¾ÑÑ‚Ð¾Ñ‡Ð½Ð¾Ð³Ð¾ Ñ€ÐµÑÐ¿Ð¸Ñ€Ð°Ñ‚Ð¾Ñ€Ð½Ð¾Ð³Ð¾ ÑÐ¸Ð½Ð´Ñ€Ð¾Ð¼Ð° (MERS-CoV), Ð° Ð² Ð´ÐµÐºÐ°Ð±Ñ€Ðµ 2019 Ð³ Ð¾Ñ‚Ð¼ÐµÑ‡ÐµÐ½Ñ‹ ÑÐ»ÑƒÑ‡Ð°Ð¸ SARS-CoV-2 (COVID-19), Ñ‚Ñ€Ð°Ð½ÑÑ„Ð¾Ñ€Ð¼Ð¸Ñ€Ð¾Ð²Ð°Ð²ÑˆÐ¸ÐµÑÑ Ð² Ð¿ÐµÑ€Ð²Ñ‹Ðµ Ð¼ÐµÑÑÑ†Ñ‹ 2020 Ð³ Ð² Ð¿Ð°Ð½Ð´ÐµÐ¼Ð¸ÑŽ Ð’Ð¾ Ð²ÑÐµÑ… Ñ‚Ñ€ÐµÑ… ÑÐ»ÑƒÑ‡Ð°ÑÑ… Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ðµ Ñ‡Ð°ÑÑ‚Ð¾ Ð¿Ñ€Ð¸Ð²Ð¾Ð´Ð¸Ð»Ð¾ Ðº Ñ‚ÑÐ¶ÐµÐ»Ñ‹Ð¼Ð¸ Ð±Ñ€Ð¾Ð½Ñ…Ð¾Ð»ÐµÐ³Ð¾Ñ‡Ð½Ñ‹Ð¼Ð¸ Ð¿Ð¾Ñ€Ð°Ð¶ÐµÐ½Ð¸ÑÐ¼Ð¸, Ð²Ð°Ñ€ÑŒÐ¸Ñ€Ð¾Ð²Ð°Ð²ÑˆÐ¸Ð¼ Ð¾Ñ‚ ÑÑƒÑ…Ð¾Ð³Ð¾ Ð¸Ð·Ð½ÑƒÑ€Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ð¾Ð³Ð¾ ÐºÐ°ÑˆÐ»Ñ Ð´Ð¾ Ð¾ÑÑ‚Ñ€Ð¾Ð³Ð¾ Ñ€ÐµÑÐ¿Ð¸Ñ€Ð°Ñ‚Ð¾Ñ€Ð½Ð¾Ð³Ð¾ Ð´Ð¸ÑÑ‚Ñ€ÐµÑÑ ÑÐ¸Ð½Ð´Ñ€Ð¾Ð¼Ð° (ÐžÐ Ð”Ð¡) ÐžÐ´Ð½Ð¾Ð²Ñ€ÐµÐ¼ÐµÐ½Ð½Ð¾ Ñ ÑÑ‚Ð¸Ð¼ Ð¾Ñ‚Ð¼ÐµÑ‡ÐµÐ½Ñ‹ Ð¼Ð½Ð¾Ð¶ÐµÑÑ‚Ð²ÐµÐ½Ð½Ñ‹Ðµ Ð¸Ð·Ð¼ÐµÐ½ÐµÐ½Ð¸Ñ Ð² ÑÐ¸ÑÑ‚ÐµÐ¼Ðµ Ð²Ñ€Ð¾Ð¶Ð´ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð¸Ð¼Ð¼ÑƒÐ½Ð¸Ñ‚ÐµÑ‚Ð Ñ‡Ð°Ñ‰Ðµ Ð²ÑÐµÐ³Ð¾ Ð² Ð²Ð¸Ð´Ðµ Ð²Ñ‹Ñ€Ð°Ð¶ÐµÐ½Ð½Ð¾Ð¹ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ð¾Ð¹ Ñ€ÐµÐ°ÐºÑ†Ð¸Ð¸ Ð² Ð½Ð¸Ð¶Ð½Ð¸Ñ… Ð´Ñ‹Ñ…Ð°Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ñ… Ð¿ÑƒÑ‚ÑÑ…, Ð¿Ñ€Ð¾ÑÐ²Ð»ÑÐ²ÑˆÐ¸ÐµÑÑ Ð¿Ð¾Ð²Ñ€ÐµÐ¶Ð´ÐµÐ½Ð¸ÐµÐ¼ Ð¿Ð½ÐµÐ²Ð¼Ð¾Ñ†Ð¸Ñ‚Ð¾Ð² II Ð¿Ð¾Ñ€ÑÐ´ÐºÐ°, ÑÐ²Ð»ÐµÐ½Ð¸ÑÐ¼Ð¸ Ð°Ð¿Ð¾Ð¿Ñ‚Ð¾Ð·Ð°, Ð³Ð¸Ð°Ð»Ð¸Ð½Ð¸Ð·Ð°Ñ†Ð¸ÐµÐ¹ Ð°Ð»ÑŒÐ²ÐµÐ¾Ð»ÑÑ€Ð½Ñ‹Ñ… Ð¼ÐµÐ¼Ð±Ñ€Ð°Ð½, Ð¾Ñ‡Ð°Ð³Ð¾Ð²Ñ‹Ð¼ Ð¸Ð»Ð¸ Ð³ÐµÐ½ÐµÑ€Ð°Ð»Ð¸Ð·Ð¾Ð²Ð°Ð½Ð½Ñ‹Ð¼ Ð¾Ñ‚ÐµÐºÐ¾Ð¼ Ð»ÐµÐ³ÐºÐ¸Ñ… Ð”ÐµÑÑ‚Ñ€ÑƒÐºÑ‚Ð¸Ð²Ð½Ñ‹Ðµ Ð¿Ñ€Ð¾Ñ†ÐµÑÑÑ‹ Ð² Ñ€ÐµÑÐ¿Ð¸Ñ€Ð°Ñ‚Ð¾Ñ€Ð½Ð¾Ð¼ Ð¾Ñ‚Ð´ÐµÐ»Ðµ ÑÐ¾Ð¿Ñ€Ð¾Ð²Ð¾Ð¶Ð´Ð°Ð»Ð¸ÑÑŒ Ð¼Ð¸Ð³Ñ€Ð°Ñ†Ð¸ÐµÐ¹ Ð² Ð¾Ñ‡Ð°Ð³ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ñ… Ð¼Ð¾Ð½Ð¾Ñ†Ð¸Ñ‚Ð¾Ð²/Ð¼Ð°ÐºÑ€Ð¾Ñ„Ð°Ð³Ð¾Ð² Ð¸ Ð³Ñ€Ð°Ð½ÑƒÐ»Ð¾Ñ†Ð¸Ñ‚Ð°Ñ€Ð½Ñ‹Ñ… Ð½ÐµÐ¹Ñ‚Ñ€Ð¾Ñ„Ð¸Ð»Ð¾Ð² ÐÐ° Ñ„Ð¾Ð½Ðµ Ð¿ÐµÑ€ÐµÑ‡Ð¸ÑÐ»ÐµÐ½Ð½Ñ‹Ñ… ÑÐ²Ð»ÐµÐ½Ð¸Ð¹ Ð½Ð°Ð±Ð»ÑŽÐ´Ð°Ð»Ð°ÑÑŒ Ð²Ñ‹Ñ€Ð°Ð±Ð¾Ñ‚ÐºÐ° Ð¿Ñ€Ð¾Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ñ… Ñ†Ð¸Ñ‚Ð¾ÐºÐ¸Ð½Ð¾Ð², Ð¸Ð½Ñ‚ÐµÐ½ÑÐ¸Ð²Ð½Ð¾ÑÑ‚ÑŒ ÐºÐ¾Ñ‚Ð¾Ñ€Ð¾Ð¹ Ð¼Ð¾Ð¶ÐµÑ‚ Ð½Ð°Ñ€Ð°ÑÑ‚Ð°Ñ‚ÑŒ Ð´Ð¾ Ñ†Ð¸Ñ‚Ð¾ÐºÐ¸Ð½Ð¾Ð²Ð¾Ð³Ð¾ ÑˆÑ‚Ð¾Ñ€Ð¼Ð° Ð”Ð»Ñ SARS-CoV Ñ…Ð°Ñ€Ð°ÐºÑ‚ÐµÑ€Ð½Ñ‹ ÑÐ¸Ð¼Ð¿Ñ‚Ð¾Ð¼Ñ‹ Ð²Ñ‚Ð¾Ñ€Ð¸Ñ‡Ð½Ð¾Ð¹ Ð¸Ð¼Ð¼ÑƒÐ½Ð¾Ð´ÐµÐ¿Ñ€ÐµÑÑÐ¸Ð¸, Ð¿Ñ€Ð¾ÑÐ²Ð»ÑÐ²ÑˆÐ¸ÐµÑÑ Ð² Ð¿Ð¾Ð·Ð´Ð½ÐµÐ¼ Ð½Ð°Ñ‡Ð°Ð»Ðµ ÑÐ¸Ð½Ñ‚ÐµÐ·Ð° Ð¸Ð½Ñ‚ÐµÑ€Ñ„ÐµÑ€Ð¾Ð½Ð¾Ð² Ð¸ Ð°ÐºÑ‚Ð¸Ð²Ð°Ñ†Ð¸Ð¸ ÐºÐ»ÑŽÑ‡ÐµÐ²Ð¾Ð³Ð¾ Ñ„Ð°ÐºÑ‚Ð¾Ñ€Ð° Ð²Ð¾ÑÐ¿Ð°Ð»ÐµÐ½Ð¸Ñ â€“ NLRP3 Ð¸Ð½Ñ„Ð»Ð°Ð¼Ð¼Ð°ÑÐ¾Ð¼Ñ‹ ÐŸÑ€Ð¸Ñ‡Ð¸Ð½Ð¾Ð¹ Ð¿Ð¾Ð´Ð¾Ð±Ð½Ð¾Ð¹ Ñ€ÐµÐ°ÐºÑ†Ð¸Ð¸ ÑÐ²Ð»ÑÐµÑ‚ÑÑ Â«Ð²Ð¾Ð¾Ñ€ÑƒÐ¶ÐµÐ½Ð½Ð¾ÑÑ‚ÑŒÂ» CoV Ð¾Ð±ÑˆÐ¸Ñ€Ð½Ñ‹Ð¼ Ð½Ð°Ð±Ð¾Ñ€Ð¾Ð¼ ÑÑ‚Ñ€ÑƒÐºÑ‚ÑƒÑ€Ð½Ñ‹Ñ… Ð¸ Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ñ… Ð±ÐµÐ»ÐºÐ¾Ð², Ð¾Ð±Ð»Ð°Ð´Ð°ÑŽÑ‰Ð¸Ñ… Ð¿Ñ€Ð¾Ð²Ð¾ÑÐ¿Ð°Ð»Ð¸Ñ‚ÐµÐ»ÑŒÐ½Ñ‹Ð¼Ð¸ Ð¸ Ð¸Ð¼Ð¼ÑƒÐ½Ð¾Ð´ÐµÐ¿Ñ€ÐµÑÑÐ¸Ð²Ð½Ñ‹Ð¼Ð¸ ÑÐ²Ð¾Ð¹ÑÑ‚Ð²Ð°Ð¼Ð¸ ÐžÑ‚ÑÑ€Ð¾Ñ‡ÐµÐ½Ð½Ñ‹Ð¹ ÑÐ¸Ð½Ñ‚ÐµÐ· IFN Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÐ» Ð²Ð¸Ñ€ÑƒÑÑƒ Ð°ÐºÑ‚Ð¸Ð²Ð½Ð¾ Ð¸ Ð±ÐµÑÐ¿Ñ€ÐµÐ¿ÑÑ‚ÑÑ‚Ð²ÐµÐ½Ð½Ð¾ Ñ€ÐµÐ¿Ð»Ð¸Ñ†Ð¸Ñ€Ð¾Ð²Ð°Ñ‚ÑŒ, Ð° ÐºÐ¾Ð³Ð´Ð° Ð²ÑÐµ Ð¶Ðµ Ð¾Ñ€Ð³Ð°Ð½Ð¸Ð·Ð¼ Ð·Ð°Ð¿ÑƒÑÐºÐ°Ð» ÑÐ¸Ð½Ñ‚ÐµÐ· IFN I, ÐµÐ³Ð¾ Ð´ÐµÐ¹ÑÑ‚Ð²Ð¸Ðµ Ð¾ÐºÐ°Ð·Ñ‹Ð²Ð°Ð»Ð¾ÑÑŒ Ð²Ñ€ÐµÐ´Ð½Ñ‹Ð¼ Ð¸ ÑÐ¾Ð¿Ñ€Ð¾Ð²Ð¾Ð¶Ð´Ð°Ð»Ð¾ÑÑŒ ÑƒÑ‚ÑÐ¶ÐµÐ»ÐµÐ½Ð¸ÐµÐ¼ Ñ‚ÐµÑ‡ÐµÐ½Ð¸Ñ Ð¸Ð½Ñ„ÐµÐºÑ†Ð¸Ð¸ Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±Ñ€Ð°Ð·Ð¾Ð¼, SARS Ð¼Ð¾Ð¶Ð½Ð¾ Ñ Ð¿Ð¾Ð»Ð½Ñ‹Ð¼ Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ Ð¾Ñ‚Ð½ÐµÑÑ‚Ð¸Ðº Ñ‡Ð¸ÑÐ»Ñƒ Ð¸Ð¼Ð¼ÑƒÐ½Ð¾-Ð·Ð°Ð²Ð¸ÑÐ¸Ð¼Ñ‹Ñ… Ð¸Ð½Ñ„ÐµÐºÑ†Ð¸Ð¹ Ñ Ð²Ñ‹Ñ€Ð°Ð¶ÐµÐ½Ð½Ñ‹Ð¼ Ð¸Ð¼Ð¼ÑƒÐ½Ð¾Ð¿Ð°Ñ‚Ð¾Ð»Ð¾Ð³Ð¸Ñ‡ÐµÑÐºÐ¸Ð¼ ÐºÐ¾Ð¼Ð¿Ð¾Ð½ÐµÐ½Ñ‚Ð¾Ð¼ Ð¦ÐµÐ»ÑŒ ÑÑ‚Ð¾Ð³Ð¾ Ð¾Ð±Ð·Ð¾Ñ€Ð° Ð¾Ð¿Ð¸ÑÐ°Ñ‚ÑŒ Ð½ÐµÐºÐ¾Ñ‚Ð¾Ñ€Ñ‹Ðµ Ð¼ÐµÑ…Ð°Ð½Ð¸Ð·Ð¼Ñ‹ Ñ„Ð¾Ñ€Ð¼Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ñ Ð²Ñ€Ð¾Ð¶Ð´ÐµÐ½Ð½Ð¾Ð³Ð¾ Ð¸Ð¼Ð¼ÑƒÐ½Ð½Ð¾Ð³Ð¾ Ð¾Ñ‚Ð²ÐµÑ‚Ð° Ð½Ð° Ð¸Ð½Ñ„Ð¸Ñ†Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ðµ Ð¿Ð°Ñ‚Ð¾Ð³ÐµÐ½Ð½Ñ‹Ð¼Ð¸ ÐºÐ¾Ñ€Ð¾Ð½Ð°Ð²Ð¸Ñ€ÑƒÑÐ°Ð¼Ð¸: SARS-CoV, MERS-CoV Ð¸ CoV-2 (COVID-19)
Innate Immunity in Coronavirus Infection ;врожденный Иммунитет При Коронавирусной Инфекции